Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate consisting of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, zilovertamab vedotin is rapidly internalized and directed to lysosomes where the conjugate undergoes cleavage, releasing MMAE. This process induces apoptosis in the targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate consisting of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, zilovertamab vedotin is rapidly internalized and directed to lysosomes where the conjugate undergoes cleavage, releasing MMAE. This process induces apoptosis in the targeted cells. Zilovertamab vedotin has potential applications in cancer research [1]. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zilovertamab vedotin inhibitor inhibit